Image

Global Lewy Body Dementia Treatment Market - Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Upcoming Report
  • Apr 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Lewy Body Dementia Treatment Market, By Drug Type (Cholinesterase Inhibitors, Antipsychotic Drugs, Antidepressants, Benzodiazepine, Modafinil), Application Type (Parkinson’s Disease, Alzheimer’s Disease), Mode of Purchase (Prescription and Over the Counter), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Lewy Body Dementia Treatment Market Market Analysis and Insights: Global Lewy Body Dementia Treatment Market

Global lewy body dementia treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a healthy CAGR of 4.90% in the above-mentioned research forecast period.

The lewy body dementia (LBD) is a disorder where abnormal sediments called alpha-synuclein are found in the brain. The sediments, known as Lewy bodies, affect the chemical transmission in the brain. Certain changes would lead to problems in loss of cognitive skills, difficulty in movement, behavior. One of the critical causes due to which dementia is caused is lewy body dementia. Lewy body dementia is the second common neurodegenerative dementia after Alzheimer’s disease. More than 1 million individuals in the U.S. are affected by lewy body dementia. The onset of lewy body dementia occurs at the age of 50 years and above. It affects more men than women. The diagnosis of LBD is a challenge. LBD can be diagnosed in two ways- dementia with Lewy bodies (DLB) and Parkinson's disease dementia. The symptoms start early and worsen in the coming duration. The diagnostic test to detect lewy body dementia is blood tests, brain scans (CT scan), myocardial scintigraphy to check the blood flow to the patient’s heart. The treatment is the use of medications, which are rivastigmine (Exelon), donepezil (Aricept), and galantamine (Razadyne). Other medications such as memantine (Namenda), an N-methyl-d-aspartate (NMDA)-receptor antagonist, are added to the cholinesterase inhibitor.

The increased prevalence of Parkinson’s disease and lewy body dementia in the U.S., rise in geriatric population, increased count of government initiatives, ease of oral administration, and investment by R&D in pharmaceutical companies are predicted to drive the market growth. However, the lack of health remuneration policies, unmet medical needs, rise in cost, late diagnosis of LBD and side effects are expected to hinder the market growth. The rise of emerging markets in developing countries, the rise of untapped opportunities, upcoming developments and investments and increased awareness about the treatment for LBD by conferences and symposia are the opportunities that are projected to bolster the market growth. The lack of expertise, rise in the product (drug) recalls and use of alternatives are the challenges that can hamper the market growth.

This lewy body dementia treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Lewy Body Dementia Treatment Market Scope and Market Size

The lewy body dementia treatment market is segmented on the basis of drug type, application type, mode of purchase and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of drug type, the lewy body dementia treatment market is segmented into cholinesterase inhibitors, antipsychotic drugs, antidepressants, benzodiazepine, modafinil.
  • On the basis of application, the lewy body dementia treatment market is segmented into Parkinson’s disease, Alzheimer’s disease.
  • On the basis of mode of purchase, the lewy body dementia treatment market is segmented into prescription and over the counter.
  • On the basis of distribution channel, the lewy body dementia treatment market has also been segmented into hospital pharmacies, retail pharmacies, online pharmacies and others.

Lewy Body Dementia Treatment Market Country Level Analysis

Lewy body dementia treatment market is analysed and market size information is provided by country, drug type, application type, mode of purchase and distribution channel as referenced above.

The countries covered in the lewy body dementia treatment market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America is expected to hold the largest market share due to the rise in patient population suffering from lewy body dementia, Parkinson’s disease, the rise in elderly population, increased awareness among the population base, and affordability of oral medications. Asia-Pacific is also expected to account for the second-largest market share due to ongoing research and developments for the treatment of lewy body dementia, untreated neurological conditions, and untapped opportunities in emerging markets.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Lewy body dementia treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Lewy Body Dementia Treatment Market Share Analysis

Lewy body dementia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to lewy body dementia treatment market.

The major players covered in the lewy body dementia treatment market are BioArctic AB, Eisai Co., Ltd, Sio Gene Therapies, Sumitomo Dainippon Pharma Co., Ltd, Jazz Pharmaceuticals, Inc., Immungenetics AG, Eli Lilly and Company, Noven Pharmaceuticals, Inc., Novartis AG, Bayer AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Merck KGaA, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, AbbVie Inc, WOCKHARDT, Acadia Pharmaceuticals Inc among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Customization Available: Global Lewy Body Dementia Treatment Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

Lewy Body Dementia Treatment Market is growing at a healthy CAGR of 4.90% by 2028
Global Lewy Body Dementia Treatment Market segmented By Application Type such as Parkinson’s Disease, Alzheimer’s Disease.
This lewy body dementia treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market.
The major players covered in the lewy body dementia treatment market are BioArctic AB, Eisai Co., Ltd, Sio Gene Therapies, Sumitomo Dainippon Pharma Co., Ltd, Jazz Pharmaceuticals, Inc., Immungenetics AG, Eli Lilly and Company, Noven Pharmaceuticals, Inc., Novartis AG, Bayer AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Merck KGaA, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, AbbVie Inc, WOCKHARDT, Acadia Pharmaceuticals Inc among other domestic and global players.